Preclinical studies have demonstrated that functionalizing NPs with TfR-targeting peptides significantly enhances transcytosis across BBB models, enabling deep tumor penetration [294] and facilitating the delivery of diverse therapeutics for GBM. Here, TFRC is linked to neoplasm.